Breathing problems linked to drug that treats opioid addiction

February 1, 2018, University of Tennessee at Knoxville

A drug used to treat opioid addiction could cause breathing problems in some obese patients, according to a new study from UT scientists.

Buprenorphine is a Schedule III with a lower abuse potential than methadone. It is one of three drugs approved by the US Food and Drug Administration to help patients undergoing treatment for . The UT study found that the drug impairs the ability of to vary their breathing. These findings in mice may encourage similar studies in humans, since the ability to vary breathing helps us achieve tasks such as climbing stairs and respond to challenges such as disease and surgical stress.

The discovery of the drug's previously unknown side effect could help clinicians improve patient care, said the study's lead author, Ralph Lydic, Robert H. Cole Endowed Professor of Neuroscience in the UT Department of Psychology and the Department of Anesthesiology at UT Medical Center.

The results were published today in the Online First edition of Anesthesiology, the peer-reviewed medical journal of the American Society of Anesthesiologists. The research is supported by a grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

The study comes at a time when state and federal officials are grappling with ways to combat the nation's growing opioid abuse epidemic. A recent study from the Appalachian Regional Commission, a federal economic development agency, showed that opioid abuse in Appalachia was greater and growing at a faster rate than in the rest of the country.

Lydic and researcher partner Helen A. Baghdoyan, UT professor of psychology and professor in the Department of Anesthesiology at UT Medical Center, along with a team of scientists from UT and UT Medical Center, studied both mice of normal weight and obese mice. The results show that buprenorphine impairs the ability to vary breathing.

Previous human studies report a greater risk for respiratory failure caused by opioids among obese female patients.

"Given the impressive similarity between mouse and human genes, the mouse data encourage studying the effects of buprenorphine on breathing variability in male and female obese humans," Lydic said.

The daunting challenge for clinical providers is to diminish pain and drug craving in addicted patients without causing respiratory depression, he said.

"Recovery from addiction is very difficult and, in the most successful cases, can require two or more years," he said. "Buprenorphine received FDA approval in 2002. Only now in 2018 we discover an unknown side effect in mice. The delay from 2002 to 2018 in discovering this effect of buprenorphine should help lay readers appreciate the need to support basic and clinical research."

As their next steps, Lydic and the team of scientists will conduct studies to determine the brain regions and neurotransmitters involved in 's depression of respiratory variability.

Explore further: FDA approves once-monthly injection for opioid addiction

Related Stories

FDA approves once-monthly injection for opioid addiction

December 4, 2017
(HealthDay)—Sublocade, a once-monthly injection of buprenorphine to treat opioid use disorder, has been approved by the U.S. Food and Drug Administration.

FDA warns on mixing opioid addiction treatments, other meds

September 20, 2017
The Food and Drug Administration has issued new warnings about the dangers of combining medication for opioid addiction with antidepressants and other drugs that also slow breathing and brain activity.

Methadone increases death risk in first four weeks of treatment for opioid dependence

September 16, 2015
Patients who start treatment for dependence on opioids are five times as likely to die in the first four weeks when they are prescribed the most commonly used treatment, methadone, than with an alternative treatment, buprenorphine, ...

Treat patients with addiction during, after hospitalization, researchers say

June 30, 2014
The results of a new study demonstrate that starting hospitalized patients who have an opioid (heroin) addiction on buprenorphine treatment in the hospital and seamlessly connecting them with an outpatient office based treatment ...

Starting opioid addiction treatment in the ED is cost-effective

August 16, 2017
The most cost-effective treatment for people with untreated opioid addiction who visit the emergency department (ED) is buprenorphine, a medication to reduce drug cravings and withdrawal, say Yale researchers. Their study ...

New vaccine technology shows promise as a tool to combat the opioid crisis

December 18, 2017
Researchers with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) report that an experimental heroin vaccine induced antibodies that prevented the drug from crossing the blood-brain ...

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.